Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

CKPT

Checkpoint Therapeutics Inc

Dec 13 • 04:00PM ET

3.67

Dollar change -0.13
Percentage change -3.42	%

Healthcare • Biotechnology • USA • NASD

Peers: MRK JNJ PFE NVS VRTX AMGN GILD BPMC INCY EXEL

| Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.44	Insider Own	15.69%	Shs Outstand	45.10M	Perf Week	-12.83%
Market Cap	179.21M	Forward P/E	26.21	EPS next Y	0.14	Insider Trans	-0.49%	Shs Float	41.17M	Perf Month	1.38%
Income	-46.47M	PEG	-	EPS next Q	-0.20	Inst Own	16.23%	Short Float	15.96%	Perf Quarter	56.84%
Sales	0.05M	P/S	3584.24	EPS this Y	71.45%	Inst Trans	189.41%	Short Ratio	7.89	Perf Half Y	73.11%
Book/sh	-0.27	P/B	-	EPS next Y	115.47%	ROA	-1256.40%	Short Interest	6.57M	Perf Year	14.69%
Cash/sh	0.10	P/C	38.13	EPS next 5Y	-	ROE	-	52W Range	1.36 - 4.50	Perf YTD	60.26%
Dividend Est.	-	P/FCF	-	EPS past 5Y	26.32%	ROI	-	52W High	-18.44%	Beta	1.32
Dividend TTM	-	Quick Ratio	0.29	Sales past 5Y	-47.67%	Gross Margin	-	52W Low	169.85%	ATR (14)	0.27
Dividend Ex-Date	-	Current Ratio	0.29	EPS Y/Y TTM	66.27%	Oper. Margin	-79817.02%	RSI (14)	46.84	Volatility	6.57% 7.71%
Employees	23	Debt/Eq	-	Sales Y/Y TTM	-72.51%	Profit Margin	-98868.09%	Recom	1.00	Target Price	23.50
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	21.30%	Payout	-	Rel Volume	1.48	Prev Close	3.80
Sales Surprise	-100.00%	EPS Surprise	-26.79%	Sales Q/Q	-100.00%	Earnings	Nov 12 AMC	Avg Volume	832.75K	Price	3.67
SMA20	-5.50%	SMA50	6.81%	SMA200	53.23%	Trades		Volume	1,235,468	Change	-3.42%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-14-22	Resumed	B. Riley Securities	Buy	$7
Jun-09-21	Initiated	B. Riley Securities	Buy	$18
Jan-20-21	Initiated	Cantor Fitzgerald	Overweight	$16
May-29-19	Initiated	Lake Street	Buy
Dec-08-17	Initiated	H.C. Wainwright	Buy	$11

Today 06:15PM	Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT (cosibelimab-ipdl) (GlobeNewswire)
Dec-02-24 10:18AM	Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend (PR Newswire)
Nov-14-24 04:10PM	Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire) -9.26%
Nov-12-24 04:30PM	Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates (GlobeNewswire) +8.15%
Sep-16-24 07:30AM	Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024 (GlobeNewswire)
08:00AM	Loading…
Sep-04-24 08:00AM	Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-16-24 12:00PM	What Makes Checkpoint Therapeutics (CKPT) a New Buy Stock (Zacks)
Aug-13-24 04:05PM	Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire) -5.80%
Aug-12-24 08:30AM	Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates (GlobeNewswire)
Jul-25-24 07:30AM	Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma (GlobeNewswire) +7.04%
Jul-15-24 08:00AM	GC Cell and Checkpoint Therapeutics Advance Collaborative Cancer Research (GlobeNewswire) +6.81%
Jul-02-24 08:00AM	Checkpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
07:00AM	Checkpoint Therapeutics Announces Biologics License Application Resubmission for Cosibelimab (GlobeNewswire)
Jun-24-24 07:30AM	Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission (GlobeNewswire) +15.56%
May-15-24 04:15PM	Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire) +9.20%
08:30AM	Loading…
May-13-24 08:30AM	Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference (GlobeNewswire)
May-10-24 01:52PM	CKPT Stock Earnings: Checkpoint Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
08:30AM	Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates (GlobeNewswire)
Mar-28-24 04:05PM	Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-22-24 02:52PM	CKPT Stock Earnings: Checkpoint Therapeutics Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
08:30AM	Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-18-24 08:00AM	Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors (GlobeNewswire)
Jan-29-24 08:00AM	Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-Market (GlobeNewswire) +18.45%
Jan-11-24 08:15AM	Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference (GlobeNewswire)
Dec-18-23 07:31AM	UPDATE 1-US FDA declines to approve Checkpoint Therapeutics' skin cancer therapy (Reuters) -44.88%
07:09AM	US FDA declines to approve Checkpoint Therapeutics' skin cancer therapy (Reuters)
07:00AM	U.S. Food and Drug Administration Issues Complete Response Letter for Cosibelimab Solely Due to Inspection Findings at Third-Party Manufacturer (GlobeNewswire)
Dec-11-23 12:26PM	3 Biotech Stocks to Turn $5,000 Into $1 Million: December 2023 (InvestorPlace)
Dec-05-23 08:30AM	Checkpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab with New U.S. Patent Issuance (GlobeNewswire)
Nov-13-23 05:00PM	Checkpoint Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire) +6.63%
08:30AM	Loading…
Oct-18-23 08:30AM	Checkpoint Therapeutics Announces Publication of Cosibelimab Pivotal Trial Results in the Journal for ImmunoTherapy of Cancer (GlobeNewswire)
Oct-02-23 12:53PM	Checkpoint Therapeutics Announces Exercise of Warrants for $11.13 Million in Gross Proceeds (GlobeNewswire) -5.29%
Sep-21-23 08:30AM	Checkpoint Therapeutics to Participate in the Cantor Global Healthcare Conference (GlobeNewswire)
Sep-06-23 08:30AM	Checkpoint Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-14-23 04:15PM	Checkpoint Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
04:01PM	Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Jul-31-23 08:00AM	Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market (GlobeNewswire) -16.45%
Jul-27-23 07:00AM	Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results Demonstrating Substantial Increases in Complete Response Rates in Advanced Cutaneous Squamous Cell Carcinoma (GlobeNewswire) -13.15%
Jun-28-23 08:00AM	Checkpoint Therapeutics Announces Presentation of New Cosibelimab Pharmacokinetic Data Supporting Extended-Interval Dosing (GlobeNewswire)
May-23-23 08:30AM	Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
May-21-23 10:03AM	3 Stocks With 1,000% Upside Potential (InvestorPlace)
May-15-23 04:15PM	Checkpoint Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire) +8.02%
04:01PM	Fortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Apr-02-23 08:37AM	Checkpoint Therapeutics Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
Mar-31-23 08:00AM	Checkpoint Therapeutics Announces $6.1 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -32.84%
Mar-30-23 08:00PM	Checkpoint Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights (GlobeNewswire)
04:10PM	Fortress Biotech Reports Record 2022 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-02-23 07:00AM	Checkpoint Therapeutics Announces FDA Filing Acceptance of Biologics License Application for Cosibelimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma (GlobeNewswire)
Feb-21-23 08:00AM	Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -7.82%
Jan-17-23 08:30AM	Checkpoint Therapeutics to Participate in the B. Riley Securities 3rd Annual Oncology Conference (GlobeNewswire) -8.16%
Jan-04-23 08:00AM	Checkpoint Therapeutics Submits Biologics License Application to FDA for Cosibelimab as a Treatment for Patients with Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma (GlobeNewswire) +8.47%
Jan-01-23 09:36AM	Individual investors in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) are its biggest bettors, and their bets paid off as stock gained 36% last week (Simply Wall St.)
Dec-15-22 08:00AM	Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -17.01%
Dec-05-22 04:30PM	Checkpoint Therapeutics Announces Reverse Stock Split (GlobeNewswire) -9.50% -22.84%
Nov-08-22 04:30PM	Checkpoint Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Sep-22-22 08:30AM	Checkpoint Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Sep-08-22 08:15AM	Checkpoint Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Aug-12-22 08:00AM	Checkpoint Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Jun-30-22 10:19AM	We're Keeping An Eye On Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate (Simply Wall St.)
Jun-16-22 09:29AM	Checkpoint' Cancer Therapy Shows Almost 55% Response Rate In Skin Cancer Patients (Benzinga)
07:30AM	Checkpoint Therapeutics Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Locally Advanced Cutaneous Squamous Cell Carcinoma (GlobeNewswire)
Jun-06-22 04:30PM	Checkpoint Therapeutics Announces Presentation of Pivotal Trial Results of Cosibelimab at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) -8.28%
May-19-22 08:30AM	Checkpoint Therapeutics to Participate in the H.C. Wainwright Global Investment Conference (GlobeNewswire)
May-13-22 08:30AM	Checkpoint Therapeutics Receives Pediatric Investigational Plan Waivers for Cosibelimab from the European Medicines Agency and U.K. Medicines & Healthcare Products Regulatory Agency (GlobeNewswire) +17.43%
May-12-22 04:30PM	Checkpoint Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Highlights (GlobeNewswire) +11.86%
Apr-28-22 08:00AM	Checkpoint Therapeutics Announces Data Presentation of Pivotal Trial Results of Cosibelimab to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Apr-04-22 08:15AM	Checkpoint Therapeutics to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities (GlobeNewswire)
Apr-01-22 08:30AM	Fortress Biotech Announces Virtual Two-Day R&D Summit Hosted by B. Riley Securities on Tuesday, April 5 and Wednesday, April 6, 2022 (GlobeNewswire)
Mar-31-22 07:10PM	Here's What Checkpoint Therapeutics, Inc.'s (NASDAQ:CKPT) Shareholder Ownership Structure Looks Like (Simply Wall St.)
Mar-28-22 07:30AM	Checkpoint Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-10-22 10:55AM	2 Strong Buy Penny Stocks With Over 300% Upside Potential (TipRanks) +13.77%
Jan-26-22 10:00AM	2 Biotech Stocks That Could Be 10-Baggers in 2022 (Motley Fool)
Jan-25-22 04:30PM	Checkpoint Therapeutics to Participate in the B. Riley Securities Virtual Oncology Conference (GlobeNewswire) +12.33%
11:04AM	Checkpoint Therapeutics' Cosibelimab Posts 47.4% ORR In Skin Cancer Patients (Benzinga)
10:06AM	Why Checkpoint Therapeutics Stock Is Heating Up Today (Motley Fool)
07:30AM	Checkpoint Therapeutics Announces Positive Topline Results from the Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma (GlobeNewswire)
Dec-08-21 08:30AM	Checkpoint Therapeutics Announces Initiation of CONTERNO Phase 3 Trial of Cosibelimab Combined with Chemotherapy in Patients with First-Line Non-Squamous Non-Small Cell Lung Cancer (GlobeNewswire) +5.48%
Nov-04-21 04:30PM	Checkpoint Therapeutics Reports Third Quarter 2021 Financial Results (GlobeNewswire)
07:50AM	A Look At The Intrinsic Value Of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) (Simply Wall St.)
Sep-22-21 08:30AM	Checkpoint Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference (GlobeNewswire)
Sep-09-21 08:30AM	Checkpoint Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Aug-06-21 02:13AM	Checkpoint Therapeutics (NASDAQ:CKPT) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Aug-05-21 04:30PM	Checkpoint Therapeutics Reports Second Quarter 2021 Financial Results (GlobeNewswire)
Jul-08-21 08:30AM	Checkpoint Therapeutics to Participate in the Ladenburg Thalmann 2021 Healthcare Conference (GlobeNewswire)
Jun-09-21 06:01PM	Why Checkpoint Therapeutics Skyrocketed Today (Motley Fool) +19.17%
08:02AM	5 Top Stock Gainers for Wednesday: SPI Energy, Checkpoint Therapeutics (TheStreet.com)
05:49AM	Checkpoint Therapeutics Soars on B. Riley Buy Rating, $18 Price Target (TheStreet.com)
Jun-03-21 08:00AM	Diversifying to Conquer: Fortress Biotech (FBIO) Partnering Expansion Driving Progress in Cancer Immunotherapy and Rare Disease Therapeutics (Benzinga)
May-12-21 08:00AM	Checkpoint Therapeutics Announces Completion of Enrollment in the Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma (GlobeNewswire)
May-08-21 04:23AM	What Is The Ownership Structure Like For Checkpoint Therapeutics, Inc. (NASDAQ:CKPT)? (Simply Wall St.)
May-06-21 04:15PM	Checkpoint Therapeutics Reports First Quarter 2021 Financial Results and Recent Corporate Highlights (GlobeNewswire) -14.18% +6.36%
Mar-09-21 04:30PM	Checkpoint Therapeutics Reports Full-Year 2020 Financial Results and Recent Corporate Highlights (GlobeNewswire)
01:19AM	Did You Miss Checkpoint Therapeutics' (NASDAQ:CKPT) 84% Share Price Gain? (Simply Wall St.)
Mar-04-21 08:00AM	Checkpoint Therapeutics to Participate in H.C. Wainwright Global Life Sciences Virtual Conference (GlobeNewswire) -8.86%
Mar-01-21 08:30AM	Checkpoint Therapeutics Announces Formation of Scientific Advisory Board (GlobeNewswire)
Feb-11-21 11:16AM	These 2 Penny Stocks Could Rack up Triple-Digit Gains, Say Analysts (TipRanks) +12.13%
Jan-06-21 08:30AM	Checkpoint Therapeutics to Participate in Three January 2021 Virtual Investor Conferences (GlobeNewswire)
Dec-09-20 12:15AM	Here's Why We're Not Too Worried About Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Situation (Simply Wall St.) -5.35%
Nov-27-20 01:06PM	Is Checkpoint Therapeutics, Inc. (CKPT) A Good Stock To Buy? (Insider Monkey)
Nov-09-20 08:00AM	Checkpoint Therapeutics Announces Presentation of Updated Cosibelimab Lung Cancer Results at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting (GlobeNewswire)

Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio includes CK-301, CK-101, CK-103, CK-302, and Anti-CAIX. The company was founded on November 10, 2014 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Oliviero James F III	CEO, President and Director	Jun 26 '24	Sale	2.05	24,610	50,450	1,977,170	Jun 28 08:01 PM
GRAY WILLIAM GARRETT	Chief Financial Officer	Jun 26 '24	Sale	2.06	13,038	26,858	672,186	Jun 28 08:00 PM
Oliviero James F III	CEO, President and Director	Feb 28 '24	Sale	2.06	5,894	12,142	350,836	Mar 01 08:31 PM
GRAY WILLIAM GARRETT	Chief Financial Officer	Feb 28 '24	Sale	2.07	2,035	4,212	145,224	Mar 01 08:30 PM
GRAY WILLIAM GARRETT	Chief Financial Officer	Feb 01 '24	Sale	1.95	4,115	8,024	147,259	Feb 02 08:15 PM
Oliviero James F III	CEO, President and Director	Feb 01 '24	Sale	2.01	11,900	23,919	369,680	Feb 02 08:10 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CKPT

Checkpoint Therapeutics Inc

Upgrade your FINVIZ experience